Condition: Systemic Lupus Erythematosus · Systemic Sclerosis · Dermatomyositis · Sponsor: Miltenyi Biomedicine GmbH
The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen receptors (CARs) that target the CD19 antigen on the cell surface of B cells and their precursors. During treatment, patients undergo leukapheresis, lymophodepleting chemotherapy and administration of the expanded CD19-CAR-transduced T cells.
This description comes directly from the study's public registry record.
Georg Schett, Prof. Dr. med. univ. · +49 9131 85 32093 · georg.schett@uk-erlangen.de
Daniela Bohr, Dr.med · +49 9131 85 32093 · daniela.bohr@uk-erlangen.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Erlangen | Erlangen, Bavaria, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06347718